DrugPatentWatch Database Preview
VYXEOS Drug Profile
When do Vyxeos patents expire, and when can generic versions of Vyxeos launch?
Vyxeos is a drug marketed by Celator Pharms and is included in one NDA. There are eight patents protecting this drug.
This drug has one hundred and six patent family members in nineteen countries.
The generic ingredient in VYXEOS is cytarabine; daunorubicin . There are fifteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cytarabine; daunorubicin profile page.
Summary for VYXEOS
| International Patents: | 106 |
| US Patents: | 8 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 1 |
| Clinical Trials: | 13 |
| Patent Applications: | 1 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for VYXEOS |
| Prior Art and Litigation Support | Order Prior Art and Litigation support for VYXEOS |
| DailyMed Link: | VYXEOS at DailyMed |
Generic Entry Opportunity Date for VYXEOS
Generic Entry Date for VYXEOS*:
Constraining patent/regulatory exclusivity:
NEW PRODUCT NDA:
Dosage:
POWDER;IV (INFUSION) |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Synonyms for VYXEOS
| 1256639-86-7 |
| 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone |
| CPX 351 |
| CPX-351 |
| Cytarabine / daunonubicin |
| Cytarabine mixture with daunonubicin |
| Daunonubicin / cytarabine |
| Daunonubicin and cytarabine liposomal injection |
| Daunonubicin mixture with cytarabine |
| SCHEMBL3959238 |
US Patents and Regulatory Information for VYXEOS
International Patents for VYXEOS
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2462376 | ➤ Try a Free Trial |
| Portugal | 1744764 | ➤ Try a Free Trial |
| Spain | 2650167 | ➤ Try a Free Trial |
| Australia | 2004231977 | ➤ Try a Free Trial |
| Japan | 2007533670 | ➤ Try a Free Trial |
| Japan | 4555569 | ➤ Try a Free Trial |
| Canada | 2462369 | ➤ Try a Free Trial |
| Country | Patent Number | Estimated Expiration |
Supplementary Protection Certificates for VYXEOS
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1744764 | 2018C/045 | Belgium | ➤ Try a Free Trial | PRODUCT NAME: VYXEOS (DAUNORUBICINE/CYTARABINE); AUTHORISATION NUMBER AND DATE: EU/1/18/1308 20180823 |
| 1744764 | 300960 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: COMBINATIE VAN DAUNORUBICINE EN CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827 |
| 1744764 | 122018000134 | Germany | ➤ Try a Free Trial | PRODUCT NAME: ZUSAMMENSETZUNG AUS KOMPONENTE 1 DAUNORUBICIN MIT KOMPONENTE 2 CYTARABIN; REGISTRATION NO/DATE: EU/1/18/1308 20180823 |
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
